Open-label, single-arm, multiple-dose safety, titration, and pharmacokinetic study of AFREZZA® in pediatric subjects ages 4 to 17 years with type 1 diabetes mellitus
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: type 1 diabetes mellitus
Age: Between 4 - 12 Years
Gender: Male or Female
Diagnosed with Type 1 diabetes for at least 1 year
Currently on multiple daily injections
No history of asthma
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required